

Title

Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-year Results From SERENA

Running title: SERENA 5-Year Outcomes in Psoriasis

Authors

Matthias Augustin,¹ Paul-Gunther Sator,² Ralph von Kiedrowski,³ Dimitris Rigopoulos,⁴ Marco Romanelli,⁵ Pierre-Dominique Ghislain,⁶ Tiago Torres,⁷ Dimitrios Ioannides,⁸ Cynthia Vizcaya,⁹ Andreas Clemens,⁹ Weibin Bao,¹⁰ Christelle C. Pieterse,⁹ Barbara Schulz,¹¹ Piotr Jagiello,⁹ Curdin Conrad¹²

Affiliations

1. Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Hamburg, Germany
2. Department of Dermatology, Clinic Hietzing and Karl Landsteiner Institute of Clinical Research on Skin Diseases, Vienna, Austria
3. Company for Medical Study & Service Selters (CMS3) GmbH, Selters, Germany
4. Dermatology and Venerology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
5. Dermatology Department, University of Pisa, Pisa, Italy
6. Dermatology, Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
7. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
8. First Department of Dermatology and Venereology, School of Medicine, Aristotle University, Thessaloniki, Greece
9. Novartis Pharma AG, Basel, Switzerland
10. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
11. GKM Gesellschaft für Therapieforchung mbH, Munich, Germany
12. Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland

Corresponding author

Professor Curdin Conrad,
Department of Dermatology,
CHUV University Hospital and University of
Lausanne (UNIL), Lausanne, Switzerland

Email: Curdin.Conrad@chuv.ch


Phone: +41213147060

This document includes:

- Suppl. Figures 1-3
- Suppl. Tables 1-3


Supplementary figures

Figure S1. Retention rate of secukinumab by disease duration in patients with moderate to severe psoriasis from year 1 through year 5




N, total number of patients.

Figure S2. Proportion of patients achieving PASI90 and PASI100 after the start of secukinumab stratified by biologic pre-treated vs biologic naïve



Percentages are based on the number of patients with non-missing data. Patients were treated with secukinumab for a mean±SD duration of 1.05±0.64 years prior to enrolment. n, number of patients with non-missing data. PASI, Psoriasis Area and Severity Index; SD, standard deviation.

Figure S3: Proportion of patients achieving PASI90 and PASI100 responses after the start of secukinumab treatment through to year 5 by disease duration



Percentages are based on the number of patients with non-missing data. Patients were treated with secukinumab for a mean±SD duration of 1.05±0.64 years prior to enrolment. n, number of patients with non-missing data; PASI, Psoriasis Area and Severity Index; SD, standard deviation.

Supplementary tables

Table S1. Percentage of patients with psoriasis by treatment type taken concomitantly to secukinumab

Psoriasis treatments taken concomitantly to secukinumab, n (%)	Psoriasis (N=1740)
No documented psoriasis treatment	898 (51.6)
Topical treatments	608 (34.9)
Conventional systemic treatments (and phototherapy)	42 (2.4)
Biologic treatments	42 (2.4)
Topical & conventional systemic treatments (and phototherapy)	69 (4.0)
Topical & biologic treatments	63 (3.6)
Conventional systemic treatments (and phototherapy) and biologic treatments	7 (0.4)
Topical, conventional systemic treatments (and phototherapy) and biologics	11 (0.6)

N, number of patients in the population; n, number of patients with non-missing data.

Table S2: Mean total PASI score at the start of secukinumab treatment and through year 5 (by disease duration)

Total PASI score, mean±SD	<2 years N=157	≥2 to <5 years N=189	≥5 to <15 years N=537	≥15 years N=841
Treatment start	23.7±14.1	21.1±12.7	21.4±13.6	20.5±12.5
Year 1	1.7±3.5	2.5±4.4	2.4±4.1	2.3±3.8
Year 2	1.6±3.1	2.4±7.0	2.3±3.8	2.4±3.9
Year 3	1.6±3.1	2.0±2.9	2.0±3.4	2.2±4.0
Year 4	1.0±2.3	1.0±1.5	1.5±2.7	1.9±2.9
Year ≥5	0.7±1.4	1.2±2.3	1.8±3.6	2.0±3.4

N, total number of patients; n, number of patients with non-missing data; PASI, Psoriasis Area and Severity Index; SD, standard deviation.

Table S3: Exposure adjusted incidence rate for development of PsA in patients with psoriasis (by disease duration)

Patients with psoriasis without PsA at first secukinumab treatment								
PsA development after the first secukinumab	<2 years N=139		≥2 to <5 years N=169		≥5 to <15 years N=430		≥15 years N=604	
	n (%)	EAIR	n (%)	EAIR	n (%)	EAIR	n (%)	EAIR
	4 (2.88)	0.61	5 (2.96)	0.63	20 (4.65)	1.04	32 (5.30)	1.19
Patients with psoriasis without PsA at enrolment								
PsA development during	<2 years N=137		≥2 to <5 years N=168		≥5 to <15 years N=419		≥15 years N=599	
	n (%)	EAIR	n (%)	EAIR	n (%)	EAIR	n (%)	EAIR
	2 (1.46)	0.38	4 (2.38)	0.65	9 (2.15)	0.62	27 (4.51)	1.33
EAIR, exposure-adjusted incidence rate per 100 patient years at risk; N, number of patients with psoriasis free from PsA; n, number of patients with at least one event; PsA, psoriatic arthritis.								